Sun Nelson 4
4 · Aardvark Therapeutics, Inc. · Filed Feb 19, 2025
Insider Transaction Report
Form 4
Sun Nelson
Chief Financial Officer
Transactions
- Conversion
Common Stock
2025-02-14+7,001→ 89,484 total - Purchase
Common Stock
2025-02-14$16.00/sh+10,000$160,000→ 99,484 total - Conversion
Series C Convertible Preferred Stock
2025-02-14−59,332→ 0 total→ Common Stock (7,001 underlying)
Footnotes (1)
- [F1]The Series C Convertible Preferred Stock of Aardvark Therapeutics, Inc. (the "Issuer") automatically converted on an 8.474-for-1 basis into shares of the Issuer's common stock ("Common Stock") immediately prior to the closing of the Issuer's initial public offering of its Common Stock. The Series C Convertible Preferred Stock had no expiration date.